Clinical trial TROPION-Breast02
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)
Organ | Breast |
---|---|
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | AstraZeneca |
EudraCT Identifier | 2021-005223-21 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05374512 |
Last update |